Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Anaplastic Astrocytoma Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Anaplastic Astrocytoma Overview | 9 | 1 |
| Pipeline Products for Anaplastic Astrocytoma Comparative Analysis | 10 | 1 |
| Anaplastic Astrocytoma Therapeutics under Development by Companies | 11 | 1 |
| Anaplastic Astrocytoma Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Anaplastic Astrocytoma Pipeline Products Glance | 13 | 2 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Anaplastic Astrocytoma Products under Development by Companies | 15 | 1 |
| Anaplastic Astrocytoma Products under Investigation by Universities/Institutes | 16 | 1 |
| Anaplastic Astrocytoma Companies Involved in Therapeutics Development | 17 | 13 |
| AngioChem Inc. | 17 | 1 |
| Astellas Pharma Inc. | 18 | 1 |
| Axelar AB | 19 | 1 |
| Boehringer Ingelheim GmbH | 20 | 1 |
| Burzynski Research Institute, Inc. | 21 | 1 |
| Cavion LLC | 22 | 1 |
| Celldex Therapeutics, Inc. | 23 | 1 |
| Millennium Pharmaceuticals Inc | 24 | 1 |
| Novartis AG | 25 | 1 |
| Orbus Therapeutics, Inc. | 26 | 1 |
| Pfizer Inc. | 27 | 1 |
| Tocagen Inc. | 28 | 1 |
| TVAX Biomedical, Inc. | 29 | 1 |
| Anaplastic Astrocytoma Therapeutics Assessment | 30 | 10 |
| Assessment by Monotherapy Products | 30 | 1 |
| Assessment by Combination Products | 31 | 1 |
| Assessment by Target | 32 | 2 |
| Assessment by Mechanism of Action | 34 | 2 |
| Assessment by Route of Administration | 36 | 2 |
| Assessment by Molecule Type | 38 | 2 |
| Drug Profiles | 40 | 73 |
| afatinib dimaleate Drug Profile | 40 | 13 |
| alisertib Drug Profile | 53 | 5 |
| Antineoplaston Therapy Drug Profile | 58 | 3 |
| AXL-1717 Drug Profile | 61 | 2 |
| bendamustine hydrochloride Drug Profile | 63 | 3 |
| CDX-1401 Drug Profile | 66 | 3 |
| Cellular Immunotherapy for Gliomas Drug Profile | 69 | 1 |
| Cellular Immunotherapy for Oncology Drug Profile | 70 | 1 |
| DNX-2401 Drug Profile | 71 | 3 |
| eflornithine hydrochloride Drug Profile | 74 | 2 |
| flucytosine + TBio-01 Drug Profile | 76 | 1 |
| flucytosine ER + vocimagene amiretrorepvec Drug Profile | 77 | 7 |
| irinotecan hydrochloride + TBio-02 Drug Profile | 84 | 1 |
| M-032 Drug Profile | 85 | 1 |
| mibefradil dihydrochloride Drug Profile | 86 | 3 |
| nilotinib Drug Profile | 89 | 5 |
| p28 Drug Profile | 94 | 2 |
| paclitaxel trevatide Drug Profile | 96 | 5 |
| palbociclib Drug Profile | 101 | 11 |
| TVI-Brain-1 Drug Profile | 112 | 1 |
| Anaplastic Astrocytoma Dormant Projects | 113 | 1 |
| Anaplastic Astrocytoma Discontinued Products | 114 | 1 |
| Anaplastic Astrocytoma Product Development Milestones | 115 | 2 |
| Featured News &Press Releases | 115 | 1 |
| Sep 26, 2016: Orbus Therapeutics Announces Enrollment of First Patient in Phase 3 Trial in Late-Stage Brain Cancer | 115 | 1 |
| Dec 07, 2015: Burzynski Research Institute Announces Favorable Objective Response Rates and Overall Survival in Adults with Anaplastic Astrocytoma Following Antineoplastons A-10 and AS2-1 | 115 | 1 |
| Jun 18, 2015: Burzynski Research Institute Announces Publication of Phase II Results in Adults with Recurrent Anaplastic Astrocytoma | 116 | 1 |
| Appendix | 117 | 2 |
| Methodology | 117 | 1 |
| Coverage | 117 | 1 |
| Secondary Research | 117 | 1 |
| Primary Research | 117 | 1 |
| Expert Panel Validation | 117 | 1 |
| Contact Us | 117 | 1 |
| Disclaimer | 118 | 1 |